@transgene.bsky.social  et NEC.Bio B.V signent un accord de licence pour préparer les prochaines étapes de développement de #TG4050 dans les cancers de la tête et du cou.
📰Lire le communiqué de presse 👉 https://shorturl.at/VbhDh

@transgene.bsky.social  and #NEC.Bio B.V Sign License Agreement to Prepare the Next Steps of the Development of #TG4050 in Head and Neck Cancer
📰Read the press release 👉 https://shorturl.at/7BAQE

@transgene.bsky.social is proud that our Chief Scientific Officer, #MaurizioCeppi, will join the 8th International Neoantigen Summit 2025 in Amsterdam in June.
His presentation will highlight the latest data related to our #individualized neoantigen cancer vaccine, #TG4050, from the myvac® platform.